Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2019 Aug 13;13(6):1180–1181. doi: 10.1177/1932296819868698

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Diabetes Technology Society

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Change in self-reported HbA1c post-tubeless insulin pump therapy initiation compared to prior treatment modality.

The percentage of respondents reporting HbA1c within a given range pre-tubeless insulin pump (black bars) and post-tubeless insulin pump (gray bars) is plotted for all respondents (N = 143) and stratified by prior therapy: prior multiple daily injections (N = 103) and prior other pump (N = 40). The proportion of respondents meeting the American Diabetes Association(ADA)⁷ treatment target of HbA1c <7% was significantly higher post-tubeless pump overall (P < .0001) and for prior multiple daily injection users (P < .0001), and was higher for prior users of other insulin pumps but did not reach significance (P = .13). Overall, there was a significant (P < .0001) shift in self-reported HbA1c range from high to lower levels associated with tubeless insulin pump use.